CLAIMS

1. P2X purinergic receptor antagonist for the treatment of demyelinating and autoimmune diseases, preferably multiple sclerosis, in mammals including man.

2. P2X purinergic receptor antagonist for the treatment of demyelinating and autoimmune diseases in accordance with claim 1 characterised because the purinergic receptor is preferably a P2X7 receptor.

3. P2X purinergic receptor antagonist for the treatment of demyelinating and autoimmune diseases in accordance with claim 1 characterised because the antagonist is a wide spectrum antagonist of P2X receptors or a selective antagonist of a P2X7 receptor, such as o-ATP.

4. P2X purinergic receptor antagonist for the treatment of demyelinating and autoimmune diseases in accordance with claim 1 and 3 characterised because the aforementioned antagonist can be selected from between PPADS, iso-PPADS, Suramin, Evans Blue, NF023, NF279, BBG, NF449, o-ATP, KN62, PPNDS, RB2, MRS2220, Ip51, TNP-ATP or HMA.

5. Use of an antagonist of P2X purinergic receptors in the preparation of a drug for the treatment of demyelinating and autoimmune diseases, preferably multiple sclerosis, in mammals including man.

6. Use of an antagonist of P2X purinergic receptors in accordance with claim 5 characterised because the aforementioned purinergic receptors are preferably P2X7 receptors.

7. Use of an antagonist of P2X purinergic receptors in accordance with claim 5 characterised because the aforementioned antagonist is a wide spectrum antagonist for P2X receptors or a selective antagonist of a P2X7 receptor, such as o-ATP.

8. Use of an antagonist of P2X purinergic receptors in accordance with claim

5 to 7 characterised because the aforementioned antagonist can be selected from between PPADS, iso-PPADS, Suramin, Evans Blue, NF023, NF279, BBG, NF449, o-ATP, KN62, PPNDS, RB2, MRS2220, Ip51, TNP-ATP or HMA.

9. A pharmaceutical composition which comprises of at least one P2X purinergic receptor antagonist and at least one pharmaceutically acceptable excipient.

10. A pharmaceutical composition in accordance with claim 9 characterised because the antagonist is a wide spectrum antagonist for P2X receptors or a selective antagonist of a P2X7 receptor, such as o-ATP.

11. A pharmaceutical composition in accordance with claim 9 to 10 characterised because the aforementioned antagonist is selected from between PPADS, iso-PPADS, Suramin, Evans Blue, NF023, NF279, BBG, NF449, o-ATP, KN62, PPNDS, RB2, MRS2220, Ip51, TNP-ATP or HMA.